Article: Naratriptan

Naratriptan
Systematic (IUPAC) name
N-methyl-2-[3-(1-methyl-4-piperidyl )-1H-indol-5-yl]-ethanesulfonamide
Identifiers
CAS number	121679-13-8
ATC code	N02CC02
PubChem	4440
DrugBank	APRD00220
Chemical data
Formula	C17H25N3O2S
Mol. weight	335.465 g/mol
Pharmacokinetic data
Bioavailability	74%
Metabolism	Hepatic
Half life	5-8 hours
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	C: (US) B3: (AUS)
Legal status	Prescription only
Routes	Oral

Naratriptan (Amerge®) is a triptan drug developed by Glaxo Wellcome Inc. and is used for the treatment of migraine headaches. Naratriptan is available in 2.5mg tablets. It is a selective 5-hydroxytryptamine1 receptor subtype agonist. Naratriptan hydrochloride is chemically designated as N-methyl-3-( 1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide.

Some side effects of the drug include vision changes, tingling sensations, tiredness or weakness, upset stomach, dizziness, and warm/cold temperature sensations. The Food and Drug Administration (FDA) approved Amerge on February 11, 1998.

Side effects

Dizziness, drowsiness, tingling of the hands or feet, unusual tiredness, nausea, dry mouth and unsteadiness. If these effects persist or worsen, notify your doctor promptly. Unlikely but report promptly: chest pain/pressure, throat pain/pressure, unusually fast/slow/irregular pulse, one-sided muscle weakness, vision problems, cold/bluish hands or feet, stomach pain, bloody diarrhea, mental/mood changes, fainting. In the unlikely event you have a serious allergic reaction to this drug, seek immediate medical attention. Symptoms of a serious allergic reaction include: rash, itching, swelling, severe dizziness, trouble breathing.